



AHCL/ SE/ 18 /2018-19

May 28, 2018

The National Stock Exchange of India Limited "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051 ISIN: INE098F01023	BSE Limited Department of Corporate Services 1 st Floor, P.J. Towers, Dalal Street, Mumbai 400 001
Symbol : AMRUTANJAN	Scrip Code: 590006

Dear Sir/ Madam,

Sub: Submission of Newspaper Advertisement

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith newspaper advertisement published in 'Financial Express' and 'Malai Sudar', both dated May 26, 2018 regarding the audited financial results for the Quarter and Year ended March 31, 2018.

For **Amrutanjan Health Care Limited**


(M. SRINIVASAN)
Company Secretary & Compliance Officer



Encl: a/a

Amrutanjan Health Care Limited

103, (Old No. 42-45), Luz Church Road,
Mylapore, Chennai - 600 004
Tamil Nadu, India.
Tel : +91-44 - 2499 4465
+91-44 - 2466 9000
Fax : +91-44 - 2499 4585

E-mail : customercare@amrutanjan.com
Web Site : www.amrutanjan.com
Toll Free No. : 1 - 800 - 425 - 4545
CIN - L24231TN1936PLC000017

AMRUTANJAN HEALTH CARE LIMITED

REGD. OFFICE : NEW NO.103 (OLD NO. 42-45),
LUZ CHURCH ROAD, MYLAPORE, CHENNAI - 600 004.

email id: investors@amrutanjan.com

website: www.amrutanjan.com

CIN No: L24231TN1936PLC000017

Extract of Audited Financial Results for the Quarter / Year Ended 31st March 2018


MOST TRUSTED BRAND

★ Amrutanjan Balm moved up from a ranking of 134 in 2016 to 79 in 2017

★ Amrutanjan Balm is among the top 5 gainers across various categories in India

★ Amrutanjan Balm is ranked 6th among OTC top 10 brands in India

Source: Economic Times Brand Equity February 14-20, 2018



Particulars	Quarter Ended	Quarter Ended	Year Ended	Year Ended
	31-Mar-18	31-Mar-17	31-Mar-18	31-Mar-17
	Audited	Audited	Audited	Audited
Total Income from Operations (net)	7,467.97	6,954.95	22,471.40	21,719.12
Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)*	1,112.06	696.63	3,092.70	3,363.58
Net Profit for the period before Tax (after Exceptional and/or Extraordinary items)	1,112.06	696.63	3,279.38	3,363.58
Net Profit for the period after Tax (after Exceptional and/or Extraordinary items)	571.61	262.79	1,997.30	2,179.91
Total Comprehensive Income for the period [(comprising Profit / (loss) for the period (after tax) and Other comprehensive Income (after tax)]	561.15	217.60	1,971.84	2,138.22
Equity Share Capital	292.31	292.31	292.31	292.31
Reserves (excluding Revaluation Reserve)	12,573.60	11,279.00	12,573.60	11,279.00
Earnings Per Share (Rs.2/- each)**				
Basic	3.91	1.80	13.67	14.92
Diluted	3.91	1.80	13.67	14.92

* Profit Before Tax (before & After exceptional and / or Extraordinary items) Includes both Profit before tax from Continuing Operations & Discontinued Operations.

** EPS Includes EPS from Continuing & Discontinued operations.

1. The above is an extract of the detailed format of Quarterly and Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Annual Financial Results are available on the Stock Exchange websites www.bseindia.com and www.nseindia.com and on the Company's website www.amrutanjan.com

2. The above financial results for the quarter and year ended March 31, 2018 in respect of Amrutanjan Health Care Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on May 24, 2018. The statutory auditors have audited the above results for the year ended March 31, 2018 and have issued an unmodified opinion.

3. Beginning April 1, 2017, the Company has for the first time adopted Indian Accounting Standards ('IND AS') with a transition date of April 1, 2016. These financial results have been prepared in accordance with IND AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules and regulations thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated July 5, 2016.

4. The Company has also prepared a reconciliation of the net profit for the corresponding period / year under the previously applicable Generally Accepted Accounting Principles ('Previous GAAP') with the total comprehensive income as reported in these financial results under IND AS. The net profit reconciliation for the quarter and year ended March 31, 2017 are presented below:

Net Profit Reconciliation	Quarter ended March 31, 2017	Year ended March 31, 2017
Net Profit attributable to the shareholders of the Company as per previous GAAP	314.71	2,140.92
Adjustments on account of business combination under common control (also refer note 6 below)	(25.98)	20.35
Fair valuation of investments	(71.13)	(23.05)
Actuarial gain / (loss) on employee defined benefit plans recognised in OCI	91.11	73.71
Income tax impact on above adjustments	(13.90)	(10.42)
Net profit for the period / year as per IND AS (A)	294.81	2,201.51
Other Comprehensive Income (OCI)		
Actuarial gain / (loss) on employee defined benefit plans recognised in OCI, net of tax (B)	(77.21)	(63.29)
Total Comprehensive Income as reported under IND AS (A) + (B)	217.60	2,138.22

5. In accordance with the requirements of IND AS 18, revenues pertaining to period commencing from July 01, 2017 is net of Goods and Service Tax ('GST'). However, revenues for the quarter and year ended March 31, 2017 are inclusive of excise duty.

6. The Board of Directors of the Company, in their meeting held on August 11, 2016, approved the scheme of amalgamation of its wholly owned subsidiary Amrutanjan Pharmaessence Private Limited ('APPL') with the Company. During the year, the Company had received the Court Order dated July 13, 2017 to effect such scheme. Pursuant to the requirements of IND AS 103 - Business Combinations, the Company has accounted this business combination involving entities under common control using the pooling of interest method in the financial results. Accordingly, the financial information presented for prior periods have been restated as if the combination had occurred from beginning of April 1, 2016.

7. Exceptional item represents profit on sale of land and building during the previous quarter ended December 31, 2017.

For Amrutanjan Health Care Limited

Place : Chennai
Date : 24th, May 2018

-s/d
S. Sambhu Prasad
Chairman & Managing Director

